TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- The Obesity Action Coalition (OAC) welcomes today's announcement from the White House outlining new agreements with pharmaceutical manufacturers to ...
MADRID, Spain—Stopping oral anticoagulation (OAC) improves outcomes among patients who remain free from atrial arrhythmia recurrences for at least a year after catheter ablation for atrial ...
TAMPA, Fla., Feb. 13, 2025 /PRNewswire/ -- The Obesity Action Coalition (OAC) is proud to celebrate its 20 th Anniversary, marking two decades of empowering individuals affected by the disease of ...
Despite secondary prevention with oral anticoagulation (OAC), the risk for recurrent ischemic stroke (IS) and mortality is high in patients with atrial fibrillation (AF). However, OAC discontinuation ...
In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...
Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” campaign—and it’s got some big-name backers to help. Eli Lilly, Novo Nordisk, Amgen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results